Incyte Corporation (INCY) key performance indicators and operating metrics (14 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP net income (loss) | 374.43M | FY2026-Q1 |
| Jakafi net product revenues | 758M | FY2026-Q1 |
| GAAP cost of product revenues | 104.52M | FY2026-Q1 |
| Non-GAAP cost of product revenues | 98.26M | FY2026-Q1 |
| Non-GAAP EPS (diluted) | 1.81 USD_per_share | FY2026-Q1 |
| Non-GAAP operating (loss) income | 393.67M | FY2026-Q1 |
| GAAP selling, general & administrative (SG&A) | 328.09M | FY2026-Q1 |
| GAAP research & development (R&D) | 515.9M | FY2026-Q1 |
| Non-GAAP selling, general & administrative (SG&A) | 304.06M | FY2026-Q1 |
| Total R&D expenses ex upfront consideration | 476.68M | FY2026-Q1 |
| Opzelura net product revenues | 207M | FY2025-Q4 |
| Total net product revenues | 1.22B | FY2025-Q4 |
| Niktimvo net product revenue | 56M | FY2025-Q4 |
| Non-GAAP EPS (basic) | 1.18 USD_per_share | FY2025-Q1 |
Back to INCY overview · INCY earnings · INCY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.